Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


